1. Should Financial Incentives be Used to Differentially Reward ‘Me-Too’ and Innovative Drugs?

   • Brita Pekarsky

   Current Opinion 23 September 2012 Pages: 1 - 17

2. Adverse Drug Interactions

   • Ryan Mayhew
   • June M. McKoy
   • Charles L. Bennett

   Commentary 23 September 2012 Pages: 19 - 22

   

3. The Cost and Incidence of Prescribing Errors Among Privately Insured HIV Patients

   • Fred J. Hellinger
   • William E. Encinosa

   Original Research Article 23 September 2012 Pages: 23 - 34

   

4. Cost Effectiveness of Rituximab Maintenance Therapy in Follicular Lymphoma

   • Eric Deconinck
   • Houda Miadi-Fargier
   • Pauline Brice

   Original Research Article 23 September 2012 Pages: 35 - 46

   

5. Cost Effectiveness of Intensive Lipid-Lowering Treatment for Patients with Congestive Heart Failure and Coronary Heart Disease in the US

   • Virginia M. Rosen
   • Douglas C. A. Taylor
   • Milton C. Weinstein

   Original Research Article 23 September 2012 Pages: 47 - 60

   

6. A Policy Model to Evaluate the Benefits, Risks and Costs of Warfarin Pharmacogenomic Testing

   • Lisa M. Meckley
   • James M. Gudgeon
   • David L. Veenstra

   Original Research Article 23 September 2012 Pages: 61 - 74

   

7. Erlotinib

   • Katherine A. Lyseng-Williamson

   Adis Pharmacoeconomic Drug Evaluation 23 September 2012 Pages: 75 - 92